10+ Highly Rated CAR T Therapy for Acute Myeloid Leukemia AML Clinics in China

For CAR T Therapy for AML in China, top-rated clinics with strong patient recommendations and advanced capabilities include Beijing Bioocus Medical Group and Lu Daopei Hospital. Both are recognized for their expertise in cellular therapies and comprehensive cancer care in Beijing, offering cutting-edge treatments for blood cancers like AML.

When considering CAR T-cell therapy for Acute Myeloid Leukemia in China, several clinics stand out due to their specialized focus, advanced research, and patient care. It's crucial to look for institutions with a proven track record in hematological malignancies and innovative cellular therapies.

• Beijing Bioocus Medical Group: This institution is frequently cited for its advanced gene therapy and CAR T-cell therapy programs in Beijing. They have a high patient satisfaction rate, indicating strong clinical outcomes and patient support. Their focus on innovative treatments for various medical conditions, including specific CAR T protocols for blood cancers, makes them a notable choice.
• Lu Daopei Hospital: Located in Beijing, this hospital is renowned for its expertise in blood diseases, including advanced CAR T-cell therapy and bone marrow transplantation for various blood cancers and immune disorders. Their specialized approach and dedicated units for cellular therapies contribute to their reputation.
• Other prominent medical centers like the International Hospital of Peking University and Hebei Yanda International Hospital, also in Beijing, offer multispecialty care, including oncology and advanced treatments that may encompass cellular therapies. Additionally, Kanglin Biotec - Gene Therapy Center, with locations in Guangzhou and Hangzhou, focuses on cutting-edge gene therapy, which often overlaps with CAR T-cell research and application.

To choose a reputable AML CAR T-cell therapy clinic in China, prioritize facilities with international accreditations like JCI, extensive experience with AML-specific protocols, and in-house cell manufacturing capabilities. Look for transparency in patient outcomes, robust safety measures, and comprehensive international patient services.

Selecting the right CAR T therapy clinic for AML is a significant decision. It requires thorough research to ensure you receive high-quality, safe, and effective care. Here’s a detailed approach:

• Accreditation and Certifications: Verify if the clinic holds international accreditations such as Joint Commission International (JCI). These accreditations signify adherence to global standards for patient safety and quality of care. Chinese national accreditations for specialized treatments are also important indicators.
• Specialization and Experience: Inquire about the clinic's specific experience with AML CAR T-cell therapy. Ask about the number of AML cases they have treated, their success rates (complete remission, overall response, durability of response), and their expertise in managing potential complications. A dedicated hematology-oncology department and cellular therapy unit are crucial.
• Advanced Technology: Ensure the clinic has state-of-the-art facilities, including a Good Manufacturing Practice (GMP)-certified laboratory for T-cell engineering and expansion. The quality and safety of cell manufacturing directly impact treatment efficacy.
• Multidisciplinary Team: A reputable clinic will have a team of highly skilled specialists, including hematologists, oncologists, intensivists, neurologists, and specialized nurses, all experienced in CAR T-cell therapy.
• Patient Support Services: Look for clinics that offer comprehensive support for international patients, such as language interpreters, visa assistance, accommodation help, and patient navigators.

AML CAR T-cell therapy in China typically requires patients with relapsed or refractory AML who have exhausted standard treatments. Key criteria include confirmed AML diagnosis, adequate organ function (cardiac, renal, hepatic), good performance status, and absence of active infections or significant central nervous system involvement.

Eligibility criteria for CAR T-cell therapy for AML can be stringent, as the treatment is intensive and carries potential risks. Clinics conduct a thorough evaluation to determine if a patient is a suitable candidate. Common requirements often include:

• Confirmed AML Diagnosis: Patients must have a definitive diagnosis of Acute Myeloid Leukemia.
• Relapsed or Refractory Disease: The therapy is typically for patients whose AML has returned after initial treatment (relapsed) or has not responded to previous therapies (refractory). Some clinical trials might specify the number or types of prior treatments.
• Adequate Organ Function: Patients need to demonstrate healthy function of vital organs, including:
  • Cardiac Function: Healthy heart function, often assessed by echocardiogram.
  • Renal Function: Normal kidney function, checked via blood tests.
  • Hepatic Function: Healthy liver function, also assessed through blood tests.
  • Pulmonary Function: Adequate lung capacity, usually confirmed by pulmonary function tests.
• Good Performance Status: Patients need to be well enough to withstand the demanding treatment process, often measured by scales like the ECOG performance status (e.g., 0-1 or 0-2).
• No Active Systemic Infection: Patients must be free from any uncontrolled, active infections before beginning lymphodepleting chemotherapy.
• Absence of Significant Central Nervous System (CNS) Leukemia: Active leukemia in the brain or spinal cord typically excludes patients from most CAR T protocols, though exceptions can exist in specific trials.

Chinese CAR T clinics employ specialized protocols for managing side effects like Cytokine Release Syndrome (CRS) and neurotoxicity (ICANS). They utilize continuous patient monitoring, prompt administration of immunomodulating drugs like tocilizumab or corticosteroids, and have dedicated intensive care units staffed by experienced teams for severe reactions to ensure patient safety.

CAR T-cell therapy can lead to significant side effects, primarily due to the potent immune response it generates. Leading clinics in China are well-prepared to manage these complications with specialized protocols and dedicated medical teams.

Key strategies for side effect management include:

• Intensive Monitoring: Patients are closely monitored, often in dedicated CAR T units or ICUs, for several weeks post-infusion. This includes vital signs, neurological assessments, and daily blood tests to detect early signs of complications.
• Cytokine Release Syndrome (CRS) Management: CRS is the most common and potentially serious side effect, presenting with fever, hypotension, and organ dysfunction due to widespread inflammation.
  • Mild CRS is managed with supportive care (fever reducers, fluids).
  • Moderate to severe CRS often requires specific medications like tocilizumab (an IL-6 receptor blocker) to dampen the inflammatory response, and corticosteroids.
• Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Management: ICANS can manifest as confusion, language difficulties, seizures, or swelling in the brain.
  • Neurological monitoring is continuous.
  • Corticosteroids are the primary treatment to reduce brain inflammation.
  • Antiepileptic drugs may be used for seizures.
• Infection Prevention and Management: Patients are immunosuppressed after CAR T therapy, making them vulnerable to infections. Clinics implement strict infection control measures and use prophylactic antibiotics or antifungals when necessary.

The overall CAR T therapy process for AML in China generally spans 6-8 weeks. This includes initial evaluations, T-cell collection (leukapheresis), cell manufacturing (2-3 weeks), a short course of lymphodepleting chemotherapy, the CAR T infusion, and a critical 2-4 week inpatient monitoring period for managing side effects.

The CAR T-cell therapy journey is a multi-stage process that requires significant time commitment. While the cell infusion itself is brief, the preparatory and post-infusion monitoring phases are extensive.

Here's a breakdown of the typical timeline:

• Initial Evaluation (1-2 weeks): Comprehensive medical tests, consultations, and review of your medical history to confirm eligibility.
• T-cell Collection (Leukapheresis) (1 day): A procedure similar to blood donation, where your T-cells are collected from your bloodstream. This is usually an outpatient procedure.
• Cell Manufacturing (2-4 weeks): The collected T-cells are sent to a specialized laboratory where they are genetically modified and expanded. During this period, patients are usually not required to stay in the hospital and can often return home, although staying near the treatment center is often recommended.
• Bridging Therapy (variable, if needed): Some patients may require chemotherapy or other treatments to control their AML while waiting for the CAR T-cells to be manufactured.
• Lymphodepleting Chemotherapy (3-7 days): Before the CAR T-cell infusion, patients receive a short course of chemotherapy to prepare their body for the new cells. This typically requires inpatient admission.
• CAR T-cell Infusion (1 day): The engineered CAR T-cells are infused back into the patient intravenously. This is usually a quick process, but it marks the beginning of the critical monitoring phase.
• Inpatient Monitoring (2-4 weeks minimum): Patients remain hospitalized for close observation and management of potential side effects, such as Cytokine Release Syndrome (CRS) and neurotoxicity (ICANS). This is the most crucial part of the treatment phase.
• Outpatient Monitoring (several weeks post-discharge): After discharge, patients usually need to stay near the clinic for several more weeks for frequent follow-up appointments and continued monitoring.

To verify an AML CAR T clinic's quality in China, look for international accreditations like JCI, check their publications in peer-reviewed journals, and directly request specific clinical trial data for AML CAR T therapy outcomes. Reputable clinics are transparent about their certifications, research contributions, and patient success metrics.

Ensuring the quality and reliability of an AML CAR T clinic is paramount for patient safety and treatment efficacy. Here are practical steps to verify a clinic’s credentials:

• International Accreditations: Look for evidence of globally recognized accreditations. The Joint Commission International (JCI) is a leading organization that certifies healthcare facilities for meeting rigorous international standards for patient safety and quality. Clinics often display JCI seals on their websites; you can also cross-reference this directly on the JCI website.
• Clinical Trial Participation and Publications: Top-tier CAR T centers are often involved in ongoing clinical research and trials. Search for the clinic's name in medical databases like PubMed to find peer-reviewed publications or presentations at major oncology conferences related to their AML CAR T programs. This demonstrates their commitment to advancing the field and adherence to research standards.
• Request Outcome Data: Ask the clinic’s international patient department for specific, published data regarding their AML CAR T therapy. Inquire about:
  • Overall Response Rate (ORR)
  • Complete Remission (CR) Rate
  • Duration of Response and progression-free survival
  • Incidence and severity of key side effects (CRS, ICANS) and how they are managed.
  Reputable clinics will be transparent and willing to share this information.
• Facility Tours or Virtual Consultations: If possible, arrange a virtual tour or consult with the medical team. This can provide insight into their facilities, technology, and patient care environment.

After AML CAR T therapy in Chinese clinics, a structured follow-up plan is implemented, including regular clinic visits, blood tests, and bone marrow biopsies at specific intervals (e.g., 1, 3, 6, and 12 months) to monitor treatment response and potential long-term side effects. They typically provide comprehensive medical reports for your local oncologist.

Follow-up care is a critical component of successful CAR T-cell therapy, ensuring sustained remission and managing any late-onset complications. Chinese clinics treating international patients have established protocols for post-discharge monitoring and coordination.

The typical follow-up care involves:

• Initial Outpatient Monitoring: Immediately after discharge, patients are often required to stay near the clinic for several weeks to allow for frequent outpatient visits. These appointments focus on monitoring for delayed toxicities, infection, and early signs of AML relapse.
• Scheduled Assessments: Regular follow-up visits are scheduled at predetermined intervals (e.g., 1 month, 3 months, 6 months, 1 year, and annually thereafter). These assessments include:
  • Physical Examinations: To check overall health and recovery.
  • Blood Tests: To monitor blood counts, immune cell recovery, CAR T-cell persistence, and detect B-cell aplasia (a common side effect indicating CAR T-cell activity).
  • Bone Marrow Biopsies: Crucial for assessing minimal residual disease (MRD) and confirming remission status.
  • Imaging Scans: As needed, to monitor for any signs of disease recurrence.
• Coordination with Home Oncologist: Leading Chinese clinics are experienced in collaborating with a patient's local healthcare team. They provide a comprehensive discharge summary, detailed treatment records, and specific recommendations for ongoing care to your home oncologist, facilitating seamless long-term management.
• Telemedicine/Remote Consultations: Many clinics offer virtual follow-up options, allowing patients to consult with their Chinese medical team from their home country, especially for reviewing test results or addressing concerns without requiring physical travel.

Chinese clinics catering to international patients offer extensive support, including dedicated international patient departments, multilingual coordinators for consultations, assistance with visa applications and local accommodation, and interpreter services. This holistic support aims to ease logistical burdens and ensure patients and their families feel comfortable throughout the AML CAR T therapy journey.

Recognizing the unique challenges international patients face, top medical centers in China provide a suite of support services to ensure a smooth and stress-free experience. These services are crucial for patients undergoing complex treatments like AML CAR T therapy.

Typical support services include:

• Dedicated International Patient Department: This department serves as a central point of contact, coordinating all aspects of the patient's visit. Staff are usually fluent in multiple languages, including English, and assist with initial inquiries, appointments, and overall logistics.
• Language and Interpretation Services: Professional medical interpreters are provided for all critical communications, including consultations with doctors, explanation of treatment plans, and obtaining informed consent. This ensures clear understanding and avoids miscommunication.
• Visa and Travel Assistance: Clinics often assist with generating invitation letters required for medical visas for both the patient and accompanying family members. They may also offer guidance on travel arrangements, such as airport transfers and local transportation.
• Accommodation Support: Help is usually available for arranging suitable accommodation near the hospital, ranging from hospital guest houses to nearby hotels or serviced apartments, to ensure comfort during the extended treatment and recovery period.
• Financial Counseling: While direct billing with all international insurance providers may not be possible, clinics offer support in preparing detailed invoices and medical reports necessary for insurance reimbursement claims.
• Cultural Sensitivity and Personal Support: Staff are often trained to understand and respect diverse cultural backgrounds, providing a welcoming and comfortable environment. Some centers may also offer psychological support services.

Yes, you absolutely should compare CAR T-cell therapy protocols for AML among Chinese clinics. Different centers may target distinct AML antigens (e.g., CD123, CD33), use varied CAR construct designs, or be involved in different clinical trial phases. Inquiring about their specific data on efficacy and safety for each protocol is essential.

CAR T-cell therapy is a rapidly evolving field, and protocols can differ significantly between research institutions and commercial clinics. For AML, where CAR T is still largely investigational outside of specific trials, comparing protocols is crucial.

Here’s what to consider when comparing different protocols:

• Target Antigens: Unlike B-cell leukemias which often target CD19, AML cells can express various antigens. Chinese clinics may be developing CAR T-cells against targets such as:
  • CD33: A common myeloid antigen, but targeting it has been challenging due to potential on-target/off-tumor toxicity to healthy myeloid cells.
  • CD123: Expressed on AML blasts and leukemia stem cells, making it a promising target.
  • CLL-1: Another potential target expressed on AML cells.
  Understand which antigen each clinic's protocol targets and the rationale behind that choice.
• CAR Construct Design: The design of the Chimeric Antigen Receptor (CAR) itself can vary. Different co-stimulatory domains (e.g., 4-1BB, CD28) can influence the persistence, expansion, and anti-leukemic activity of the CAR T-cells, as well as their toxicity profile.
• Clinical Trial Phase: Determine if the treatment is part of an ongoing clinical trial (Phase 1, 2, or 3) or a compassionate use program. Clinical trials offer access to cutting-edge therapies under strict regulatory oversight, but also come with inherent uncertainties of experimental medicine.
• Published Data: Request specific data from the clinic's own experience with the particular protocol for AML. This should include response rates, remission durability, and the safety profile unique to that construct and patient population.
• Manufacturing Process: Inquire about the turnaround time for cell manufacturing and the quality control measures in place, as these can impact the viability and effectiveness of the CAR T-cells.

AML treatment centers in China serving international patients offer comprehensive language and communication support. This typically includes dedicated multilingual coordinators, professional medical interpreters for consultations and consent, and translated medical documents. This ensures clear understanding for English, Russian, Arabic, and other speaking patients and their families throughout treatment.

Effective communication is vital in medical settings, especially for complex and high-stakes treatments like AML CAR T therapy. Chinese clinics with established international patient programs prioritize robust language support to ensure patient safety and comfort.

Here’s what you can expect in terms of language and communication:

• Multilingual International Patient Coordinators: Most leading medical centers have dedicated international patient departments staffed with coordinators who are fluent in English and often other major languages such as Russian, Arabic, Spanish, or French. These coordinators act as your primary liaison and can assist with all non-medical communication.
• Professional Medical Interpreters: For all medical consultations, treatment discussions, consent processes, and daily interactions with the medical team, professional medical interpreters are typically provided. These interpreters are specifically trained in medical terminology to ensure accurate and nuanced communication between patients/families and doctors.
• Translated Medical Documents: Important documents, including treatment plans, consent forms, discharge summaries, and follow-up instructions, are often provided in English or your native language. This ensures you have a clear written record of your care.
• 24/7 Communication Channels: During your inpatient stay, there will be mechanisms in place for continuous communication with nursing staff and doctors. This might involve bilingual nurses on the ward or an on-call interpretation service available around the clock.
• Telemedicine Options: Many clinics offer telemedicine or remote consultation services, allowing for follow-up discussions with your Chinese medical team from your home country, with interpreter support if needed.

Leading CAR T-cell therapy clinics in China understand the psychological toll of AML treatment and often offer supportive services. These can include access to psychological counseling, patient support groups, and liaisons with international patient departments trained in empathy. The goal is to address mental well-being alongside physical recovery for both patients and their families.

Undergoing CAR T-cell therapy for AML can be emotionally and psychologically challenging for both patients and their families. Top clinics recognize the importance of holistic care that extends beyond physical treatment. While specific services can vary, reputable centers often aim to integrate psychological support.

Such support services might include:

• Access to Counseling: Patients may have access to psychologists or counselors who specialize in oncology and chronic illness. These professionals can help patients cope with anxiety, depression, fear of recurrence, and the overall stress associated with intense medical treatment.
• Patient Education: Providing clear and consistent information about the treatment process, potential side effects, and recovery timeline can significantly reduce anxiety. Educational materials and dedicated patient navigators help manage expectations and uncertainties.
• Support Groups: Some clinics facilitate patient support groups, either in-person or virtually, where patients can connect with others undergoing similar treatments. Sharing experiences and advice can be incredibly beneficial for mental well-being.
• Family Support: The emotional burden on family members is also acknowledged. Clinics might offer resources or counseling specifically for caregivers, helping them cope with stress and better support the patient.
• Mind-Body Programs: Some advanced medical centers may offer complementary therapies like mindfulness, meditation, or light exercise programs designed to reduce stress and promote overall well-being during recovery.
• International Patient Liaisons: The international patient department staff often play a crucial role in providing emotional reassurance and practical assistance, understanding the added stress of seeking treatment abroad.

Chinese CAR T-cell clinics for AML are actively involved in significant research and development, focusing on new target antigens (beyond CD33/CD123), dual-targeting strategies to overcome antigen escape, and improving CAR construct designs for enhanced safety and persistence. Many are conducting investigator-initiated clinical trials to refine existing therapies and explore novel approaches for relapsed/refractory AML patients.

China has emerged as a significant player in CAR T-cell therapy research and development, with numerous ongoing clinical trials, particularly for hematological malignancies. For AML, where challenges like antigen heterogeneity and on-target/off-tumor toxicity are prominent, Chinese clinics are at the forefront of innovative approaches.

Key research and development initiatives often include:

• Novel Target Antigen Identification: Researchers are continuously exploring new surface markers on AML cells that can be safely and effectively targeted by CAR T-cells, moving beyond established targets like CD33 and CD123 to find more specific and potent options.
• Dual or Multi-Targeting Strategies: To address the issue of antigen escape (where AML cells lose the target antigen, leading to relapse), clinics are developing CAR T-cells designed to recognize two or more different antigens simultaneously. This approach aims to reduce relapse rates and enhance therapeutic durability.
• Improving CAR Construct Design: Ongoing research focuses on optimizing the CAR construct itself, including modifying co-stimulatory domains, hinge regions, and intracellular signaling domains to improve CAR T-cell persistence, minimize exhaustion, and reduce toxicity.
• Allogeneic (Off-the-Shelf) CAR T-cells: While most current CAR T therapies are autologous (using the patient's own cells), many Chinese institutions are heavily invested in developing allogeneic CAR T-cells from healthy donors. This would make the therapy more accessible and faster to administer.
• Combination Therapies: Clinics are investigating combining CAR T-cell therapy with other treatments, such as chemotherapy, radiation, or checkpoint inhibitors, to enhance efficacy and overcome resistance mechanisms.
• Management of Toxicities: Research is also dedicated to better understanding and managing CAR T-related toxicities like Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), aiming to improve patient safety.

Chinese clinics ensure ethical conduct and patient safety in AML CAR T-cell trials through strict adherence to national health regulations and international guidelines like ICH-GCP. This involves robust Institutional Review Board (IRB) oversight, comprehensive informed consent processes, continuous monitoring for adverse events, and transparent reporting to regulatory bodies.

Ethical considerations and patient safety are paramount in clinical trials, especially for innovative and potentially high-risk therapies like CAR T-cell therapy for AML. Reputable Chinese clinics adhere to rigorous standards to protect trial participants.

Key measures to ensure ethical conduct and patient safety include:

• Institutional Review Board (IRB) / Ethics Committee Approval: All clinical trials must undergo extensive review and approval by an independent IRB or ethics committee. This committee assesses the scientific merit, ethical considerations, and patient safety protocols of the trial.
• Informed Consent Process: Patients (or their legal guardians) must provide fully informed consent before participating in a trial. This involves a comprehensive discussion of the treatment, its potential benefits and risks, alternative treatments, and the patient's right to withdraw at any time without penalty. All information is provided in a language the patient understands, often with professional interpreters.
• Adherence to Good Clinical Practice (GCP): Clinical trials in China are increasingly aligned with international standards such as ICH-GCP guidelines, which define ethical and scientific quality standards for designing, conducting, recording, and reporting trials involving human subjects.
• Continuous Safety Monitoring: Patients in CAR T-cell trials are subject to intensive and continuous monitoring for adverse events and toxicities. Dedicated safety committees review all adverse events to ensure patient well-being and make any necessary adjustments to the protocol.
• Data Integrity and Reporting: All clinical trial data is meticulously collected, managed, and audited to ensure accuracy and integrity. Adverse events and study outcomes are reported to relevant regulatory authorities (e.g., China's National Medical Products Administration - NMPA) in a timely and transparent manner.
• Patient Privacy and Confidentiality: Strict measures are in place to protect patient confidentiality and personal health information in accordance with privacy regulations.

The long-term outlook for AML patients receiving CAR T therapy in China is still actively being studied, but early results from clinical trials show promise, particularly for those with relapsed/refractory disease. While some patients achieve durable remissions, challenges like relapse due to antigen escape or CAR T-cell exhaustion remain. Ongoing research aims to improve persistence and overall survival.

CAR T-cell therapy for Acute Myeloid Leukemia is a relatively new and rapidly evolving field, particularly when compared to its success in B-cell malignancies. Therefore, long-term outlooks are continuously being gathered and refined through ongoing clinical trials in China and globally.

Here’s a general understanding of the long-term outlooks:

• Promising Early Results: For patients with relapsed or refractory AML who have exhausted conventional treatments, CAR T therapy has shown encouraging results in early-phase clinical trials, with some patients achieving complete remissions. These initial responses are critical, offering a new hope where few options existed.
• Challenges with Durability: A key challenge in AML CAR T therapy is achieving durable remissions. Some patients may experience relapse due to factors like:
  • Antigen Escape: AML cells might stop expressing the target antigen, making them "invisible" to the CAR T-cells.
  • CAR T-cell Exhaustion: The engineered T-cells might lose their effectiveness over time.
  • Immunosuppressive Microenvironment: The bone marrow environment in AML can hinder CAR T-cell function.
  Ongoing research in China focuses on strategies to overcome these mechanisms of resistance.
• Potential for Long-Term Remission: While not yet as consistently achieved as in some B-cell leukemias, there are patients who achieve long-term, durable remissions following successful CAR T therapy for AML. The goal of current research is to increase the number of patients who experience this long-term benefit.
• Ongoing Monitoring: Regardless of initial success, long-term follow-up is crucial. Patients will require regular monitoring for signs of relapse, late-onset side effects, and immune system recovery. This can include blood tests, bone marrow biopsies, and imaging studies for many years after treatment.
• Improved Quality of Life: For patients who achieve durable remissions, CAR T therapy can significantly improve their quality of life by reducing the burden of disease and potentially eliminating the need for continuous conventional treatments.

How PlacidWay helps individuals access CAR T Therapy for Acute Myeloid Leukemia AML in China?

PlacidWay provides detailed, up-to-date information about CAR T Therapy for Acute Myeloid Leukemia AML, including benefits, risks, and expected outcomes. We empower you with the knowledge needed to understand this cutting-edge treatment, ensuring you are fully informed before making a decision.

We help you compare treatment options in various world-class clinics in China, ensuring you find affordable choices without compromising on the quality of care. Our platform allows you to see transparent details on different facilities, helping you find the right fit for your medical and financial needs.

PlacidWay assists you in finding trusted, accredited clinics and highly experienced medical professionals specializing in CAR T Therapy for AML in China. We have a network of vetted partners, giving you peace of mind that you are connecting with reputable and successful treatment centers.

We offer personalized, one-on-one consultations to help you make informed decisions about your treatment. Our care team listens to your unique situation and helps navigate the complexities of choosing a clinic and protocol, ensuring your specific health needs are met.

Our commitment to your well-being extends beyond the treatment itself. PlacidWay ensures you have continued support after the procedure, including assistance with coordinating follow-up care and recovery plans with your chosen clinic and home doctor.

Ready to get CAR T Therapy for Acute Myeloid Leukemia AML in China? Contact us today for a personalized consultation.